Alessandro Rametta *, Valentina Guadalupi, Elena Verzoni, Giuseppe Procopio
Immunotherapy has a cardinal role in renal cancer, both in adjuvant setting and metastatic disease (first or subsequent lines). Severe Immune-Related Adverse Events (irAEs) occur in 10%-27% of patients treated with immunotherapy, but the discontinuation of the treatment due to toxicity doesn’t necessarily correlate with poor outcome. We present the case of a woman affected by metastatic clear cell renal cell carcinoma who presented a long-term response to second line treatment with Nivolumab after early interruption due to immuno-toxicity (hepatotoxicity, skin rash, hypothyroidism).
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu